Acelyrin Inc is a biopharmaceutical company focused on developing innovative therapies for patients with chronic and debilitating conditions
The company specializes in advancing treatments that target unmet medical needs, with particular emphasis on autoimmune and inflammatory diseases. Through its robust pipeline, Acelyrin aims to improve the quality of life for patients by harnessing cutting-edge science and technology to create effective and safe therapeutic options. The organization is committed to rigorous clinical research and collaboration with healthcare professionals to bring new solutions to the market.
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of ACELYRIN’s development programs or intellectual property.
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (NasdaqGS: SLRN) to Alumis Inc. (NasdaqGS: ALMS). Under the terms of the proposed transaction, shareholders of Acelyrin will receive 0.4274 shares of Alumis common stock for each share of Acelyrin that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ACELYRIN, INC. (NASDAQSLRN) to Alumis Inc. for 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock is fair to ACELYRIN shareholders.
Ademi & Fruchter LLP is investigating ACELYRIN (Nasdaq: SLRN) for possible breaches of fiduciary duty and other violations of law in its transaction with Alumis.
Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile
ACELYRIN shares are moving higher on Friday after the company announced that it will reveal Phase 2 data and announce Phase 3 plans for Subcutaneous Lonigutamab at a virtual investor event.
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2 data for subcutaneous lonigutamab further supporting its potential for a best-in-class efficacy and safety profile in Thyroid Eye Disease (TED). The event will also feature external clinician perspectives on the continuing unmet needs in TED and disclose the design for the Phase 3 LONGITUDE program, which was developed following a successful End-of-Phase 2 meeting with the FDA to be the most inclusive registrational program to date in TED. To register, click here.
